Navigation Links
Lab research may one day lead to cancer treatment using patient's own immune cells

A new line of developing research is underway that hopes to use a patient's own immune cells to fight cancer. The field, known as adoptive immunotherapy, is a specialty procedure performed in only a handful of institutions, which may one day include University Hospitals Case Medical Center.

Julian A. Kim, M.D., chief of surgical oncology at UH Ireland Cancer Center, has received a $660,000 grant from the National Institutes of Health for a five-year study that hopes to lead to new treatments using a set of immune cells, called T cells, to fight skin cancer (melanoma) and breast cancer. The research project is called "Molecular studies of T cell clones for adoptive therapy."

The pre-clinical trial, which means it will be used only in human tissues in the laboratory at this stage, will focus on identifying and harvesting T cells within the lymph nodes of patients, activating these T cells and growing them in culture in the laboratory over one to two weeks. The T cells are activated with molecular agents called interleukin-2 and anti-CD3 antibody (OKT3).

It is hoped that results from this research could lead to a safety study, called a Phase I study, in humans using this process. This pre-clinical research will help researchers learn how to most effectively select and obtain the T cells for this form of therapy. In future use with humans, the cells would be grown in the cell processing facility located in the Iris S. and Bert L. Wolstein Research Building, which opened in 2003. The activated T cells would be reinfused into the bloodstream of the same patient to train their immune system to fight the cancer.

According to Kim, the Phase I study would involve about 20 patients and would open in about five years. "If these trials prove successful, a similar approach could be developed in patients with other types of cancer as well," said Kim.


'"/>

Source:University Hospitals of Cleveland


Page: 1

Related biology news :

1. Columbia research lifts major hurdle to gene therapy for cancer
2. U of M researcher examines newly emerging deadly disease
3. NYU researchers simulate molecular biological clock
4. First atlas of key brain genes could speed research on cancer, neurological diseases
5. New research questions basic tenet of neuron function
6. Vital step in cellular migration described by UCSD medical researchers
7. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
8. UCSD researchers maintain stem cells without contaminated animal feeder layers
9. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
10. New protein discovered by Hebrew University researchers
11. First real-time view of developing neurons reveals surprises, say Stanford researchers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
(Date:3/23/2017)... report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and Touchless), Product ... by MarketsandMarkets, the market is expected to be worth USD 18.98 billion by ... Continue Reading ... ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ... implantation and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... and maternal age to IVF success. , After comparing the results from the ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... Parks Associates announced today that Tom Kerber , Director ... , October 11 in Scottsdale, Arizona . Kerber will ... safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction of ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee is ... honoring scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. ... world’s leading conference and exposition for laboratory science, which will be held February ...
Breaking Biology Technology: